

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Transcenta Holding Limited**

**創勝集團醫藥有限公司**

*(registered by way of continuation in the Cayman Islands with limited liability)*

**(Stock Code: 6628)**

## **RESIGNATION OF EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of Transcenta Holding Limited (the “**Company**”) hereby announces that Dr. Michael Ming Shi (“**Dr. Shi**”) has notified the Board that he will no longer serve as an executive director of the Company with effect from July 20, 2022 to focus on the Company’s pipeline development efforts.

Dr. Shi has confirmed that (i) he has no claim against the Company and there is no disagreement between him and the Board; and (ii) there are no matters that need to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company.

The Board would like to take this opportunity to express its appreciation to Dr. Shi for his valuable contribution to the Board of the Company during his tenure of office.

By Order of the Board  
**Transcenta Holding Limited**  
**Xueming Qian**  
*Executive Director and Chief Executive Officer*

Hong Kong, July 20, 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director and chief executive officer, Mr. Xiaolu Weng as executive Director, Dr. Yining (Jonathan) Zhao as chairman and non-executive Director, and Mr. Jiasong Tang, Dr. Jun Bao and Mr. Zhihua Zhang as independent non-executive Directors.*